Abstract | Paradigm shifts in surgery arise when surgeons are empowered to perform surgery faster, better and less expensively than current standards. Optical imaging that exploits invisible near-infrared (NIR) fluorescent light (700-900 nm) has the potential to improve cancer surgery outcomes, minimize the time patients are under anaesthesia and lower health-care costs largely by way of its improved contrast and depth of tissue penetration relative to visible light. Accordingly, the past few years have witnessed an explosion of proof-of-concept clinical trials in the field. In this Review, we introduce the concept of NIR fluorescence imaging for cancer surgery, examine the clinical trial literature to date and outline the key issues pertaining to imaging system and contrast agent optimization. Although NIR seems to be superior to many traditional imaging techniques, its incorporation into routine care of patients with cancer depends on rigorous clinical trials and validation studies.
Introduction
Improvements in preoperative imaging techniques, such as MRI and CT, have had a meaningful impact on the care of patients with cancer by facilitating early detection, improving diagnostic accuracy and staging and improving preoperative planning. 1, 2 However, during surgery, the eyes and hands of the surgeon remain the dominant 'imaging modalities' used to decide which tissues need to be resected and which tissues need to be preserved. Palpation and visual inspection are not always sufficient for discriminating between malignant and normal tissue types and can lead to incomplete resections or the unneces sary removal of healthy tissue. For example, many breast tumours are nonpalpable; consequently, the positive-margin rates are in the range of 5-49%. 3, 4 In some circumstances, ultrasonography, X-ray fluoroscopic imaging or both are used during cancer surgery to find occult tumours and define tumour vasculature, but these modalities lack the possibility of using targeted contrast agents to specifically visualize certain cell types, expose the patient and caregivers to ionizing radiation and/or require direct contact with the body. Intraoperative MRI and CT have also had a considerable role in preoperative staging and intraoperative planning of resection, especially in the field of neurosurgical image guidance. 5 However, these intraoperative systems are costly, require a complex infrastructure and are currently used p redominantly for n eurosurgery 6, 7 at specialized medical centres.
Over the past several years, intraoperative imaging using invisible near-infrared (NIR) fluorescent light has entered the surgical theatre to fill the gap between preoperative imaging and intraoperative reality. 8, 9 Whereas visible light penetrates tissue on the micrometre scale, NIR light (700-900 nm) can travel millimetres-and up to centimetres-through blood and tissue. 10 This increased photon transport improves the identification of targets below the surface. As tissue exhibits almost no autofluorescence in the NIR spectrum, the signal-tobackground contrast can be maximized using fluorescent contrast agents responsive to NIR light, creating a 'white stars in a black sky' effect. 11 In this analogy, the white stars are those structures targeted by contrast agents, which are administered prior to imaging. To date, NIR fluorescent contrast agents specific for many different targets have been developed, including agents for cancer cells, [12] [13] [14] sentinel lymph nodes (SLN), [15] [16] [17] neurological diseases, 18, 19 cardiovascular diseases, 20 ,21 skeletal processes, 22 agents cleared by the kidneys for ureter imaging 23 and hepatically cleared agents for bile-duct imaging. 24 Optically active nerve-cell agents 25, 26 have also been described, but are yet to achieve NIR wavelengths.
NIR imaging does not use ionizing radiation, making it an inherently safe technique provided that attention is paid to laser illumination levels. High levels of laser light can burn tissue and irreversibly photobleach contrast agents. Furthermore, NIR light is invisible to the human eye and does not alter the appearance of the surgical field, which minimizes the learning curve; NIR f luorescent targets are visible only on the display monitor.
Given these promising characteristics, specialized intraoperative imaging systems for open surgery, laparoscopy, 34, 35 thoracoscopy 36, 37 and robot-assisted surgery 38, 39 have become available for assessment in clinical trials. 40 Using these systems, NIR fluorescent contrast agents can be visualized with acquisition times in the millisecond range, enabling real-time guidance during surgery ( Figure 1 ). However, although these research results lay the foundation for a future revolution in patient care, excitement in the field needs to be tempered with the reality of the underlying physics. Like visible light, NIR light is attenuated by absorption and scatter in living tissue. In fact, total attenuation (the sum of attenuation from absorption and scatter) is exponential as a function of depth. Thus, only one-millionth to onebillionth of the photons launched into a tissue as fluorescence excitation is potentially recoverable as fluores cence emission, and only 10-25% of these photons are truly recoverable because of the finite quantum yield of most NIR fluorophores. 23, 41 Absorption and scatter also limit the ability to quantify NIR fluorescent signals. Without knowing (or measuring) the absorption, scatter and anisotropy of the tissue being imaged, only qualitative information can be inferred. 42 Correction for attenuation of excitation light 43 can certainly assist with target detection, although over-compensation can also cause falsepositives (structures that are labelled as NIR fluores cent but are not). Full correction for optical properties can provide quantitative measurements of NIR fluorescent signal. 44, 45 However, the use of quantitative metrics for intraoperative decision-making is still in its infancy. In the case of cancer margin detection, a qualitative 'present' or 'absent' is the relevant metric; for perfusion studies, the relative signal over time after injection of a contrast agent provides quantitative kinetic information without requiring the measurement of the optical p roperties of the tissue. 46, 47 Taken together, these limitations mean that the depth of detection for even bright targets will be constrained to approximately 5 mm, 48 but could vary slightly depending on the particular optical properties of the tissue. Although this depth is more than adequate for tumourmargin detection and many surgical applications, such as NIR fluorescence angiography of skin, effective NIR imaging in certain clinical situations must leverage the technology with other imaging modalities. In this Review, we focus on the clinical applications of NIR fluores cence imaging in cancer surgery. We describe recent developments in the field and the long-term potential benefit for patients.
Imaging systems
Over the past few years, various imaging systems have been developed by academic and industrial groups for intraoperative NIR fluorescence imaging. [27] [28] [29] [30] [32] [33] [34] [35] [36] [37] [38] [39] 49 In addition to systems for open surgery, NIR fluorescence imaging is available for laparoscopic, thoracoscopic and robot-assisted surgery, most of which mark the first production-grade development iteration. Specific challenges for these systems include the need for optimized light-sources to enable sufficient fluorescence excitation, and low-attenuation optics for NIR light, to detect low concentrations of NIR fluorophores. 8 The key issues that inform the design of the imaging system are the fluorescence excitation light, optics, usability (ergonomics) and cost. Maximizing the fluence rate (that is, the number of photons illuminating a unit surface over time) of the excitation light increases tissue penetration depth. However, limiting factors for laserbased light sources include skin and eye exposure, irreversible photochemical bleaching of the NIR fluorophore and tissue heating. 8 In general, fluence rates are restricted to the range of 10-25 mW/cm 2 to avoid these issues as well as the need for protective goggles. Additionally, initial imaging system prototypes were often assembled using off-the-shelf optics, which can distort and attenuate NIR light, causing suboptimal detection of NIR fluorescence. 8 Current versions of NIR fluorescence imaging systems are manufactured with optimized optics s pecifically for NIR light and do not suffer from these problems.
Contrast agents
Intraoperative NIR fluorescence imaging depends on the availability of an NIR fluorescent contrast agent and an intraoperative imaging system to visualize the otherwise invisible contrast agent during surgery. 8 Methylene blue has been applied clinically for many years as a visible (dark blue) dye in surgery. As methylene blue was introduced into clinical practice in an era when no formal approval was needed, no evaluation by the FDA, European Medicines Agency (EMA) or comparable authority has been performed, but it remains widely used, typically to test patency and leakage of lumenal catheters. However, if sufficiently diluted, methylene blue acts as a 700 nm fluoro phore and has recently been used in NIR fluorescence clinical studies. [50] [51] [52] Other contrast agents include indocyanine green (ICG), which fluoresces at 800 nm, and is the only NIR contrast agent approved for a small number of indications in surgery by the FDA and EMA. 53 Another agent, 5-aminolevulinic acid (5-ALA), is the major substrate for protoporphyrin synthesis and has been used clinically for tumour detection (fluorescence imaging) and tumour treatment (photodynamic therapy). 54 5-ALA (typically administered in topical or oral form) induces synthesis and accumulation of the fluorescent molecule Key points ■ Near-infrared (NIR) fluorescence imaging has been demonstrated to be feasible during cancer surgery using available imaging systems and contrast agents ■ Clinical applicability has been described in sentinel lymph-node mapping, tumour imaging, visualization of vital structures and imaging of vascularization and perfusion ■ NIR fluorescence image-guided surgery has properties that make it a good candidate for clinical acceptance, as it fulfils a clinical need, is versatile and is fast ■ Targeted contrast agents, necessary for full evaluation of this technique, are in advanced stages of clinical approval ■ As novel contrast agents are developed and camera systems are optimized, the technique should prove its true clinical value ■ Well-designed outcomes studies have yet to be performed in the field protoporphyrin IX (PpIX) in epithelial and neoplastic tissues, among them malignant gliomas and meningiomas.
55-57 PpIX has two major fluorescence emission peaks, with approximately half of its fluorescence e mission occurring in the NIR range, centred at 700 nm.
Methylene blue, ICG and 5-ALA are not ligandtargeted contrast agents, although they still exhibit specificity in some clinical situations (discussed below). The first clinical report of nontargeted (non-NIR) fluores cence surgical imaging dates back to 1948, when Moore et al. 58 used fluorescein in neurosurgical interventions for the localization of brain tumours. The first clinical report of ligand-targeted (non-NIR) fluorescence surgical imaging, which dates back to 1992, used carcino embryonic antigen-targeted antibodies labelled with fluorescein to visualize colorectal carcinomas in vivo in patients. 59 More recently, in 2012, folate-conjugated fluores cein was successfully used for the intra operative visualization of ovarian cancer cells for debulking surgery. 60 Although these landmark studies provided essential proof-of-principle, fluorescein and other visible fluorophores are not optimal for cancer surgery because high absorption and scatter result in interrogation of only the surface layer and, importantly, high autofluorescence from surrounding tissue reduces contrast.
Given this background, the existing NIR f luorophoresmethylene blue, ICG and 5-ALA-induced PpIX-have been assessed in a number of proof-of-principle clinical studies in several types of surgery (Table 1) . Interestingly, because these agents have distinct spectral properties, they could theoretically be used simultaneously in the same individual, 30 provided that the imaging system is capable of discriminating one from the other.
Clinical applications
Sentinel lymph node mapping SLN mapping is standard-of-care for a variety of cancers, including breast cancer and cutaneous melanoma. Currently, most centres perform SLN mapping using a radioactive tracer, a visible blue dye (such as iso sulfan blue or patent blue) or a combination of the two. 61, 62 Although acceptable results in terms of SLN detection and false-negative rates are obtained in most cases using these methods, both have drawbacks. Visible blue dyes stain the patient and the surgical field and cannot be visual ized below the surface of tissue. Radioactive tracers, such as technetium-99m, expose patients and caregivers to ionizing radiation, are expensive and imaging suffers from poor spatial and temporal resolution. 63 By contrast, SLN mapping using NIR fluorescence imaging can be achieved with a low concentration of the contrast agent injected, no staining of the surgical field, no ionizing radiation and an improvement over blue dyes in terms of depth sensitivity. 64 In terms of radioactivity, in countries where radiotracers are not permitted or available, NIR fluorescence imaging could replace blue dyes as routine SLN mapping methodology. For SLN mapping, ligand-targeted contrast agents are not necessary as long as the contrast agent is retained in the SLN. Moreover, given that ICG is clinically available, many SLN studies were undertaken as soon as the first intraoperative imaging systems became available ( Figure 2 ; Table 1 ). 9 In SLN mapping, the contrast agent migrates from the injection site to the SLN and, depending on the character istics of the contrast agent, might flow to higher-tier nodes over time. As flow through the SLN is undesirable, dynamic imaging-that is, continuous video imaging-can be employed, starting directly after injection to prevent misidentification of the SLN. Although counterintuitive, injection of too high a concentration of fluorophore results in a decrease of SLN signal because of quenching. 8 In dose-finding studies for SLN mapping, an ICG injection concentration of 500 μM in a volume of 1.6 mL was found to be optimal, although these values might vary between tumour types and depending on the distance between the injection site and SLN. 31 To date, NIR fluorescence-guided SLN mapping has been extensively studied in breast 30, [65] [66] [67] [68] [69] Figure 1 | The mechanics of NIR fluorescence imaging. NIR fluorescent contrast agents are administered intravenously, topically or intraparenchymally. During surgery, the agent is visualized using an NIR fluorescence imaging system of the desired form factor (above the surgical field for open surgery, or encased within a fiberscope for minimally-invasive and robotic surgery). All systems must have adequate NIR excitation light, collection optics, filtration and a camera sensitive to NIR fluorescence emission light. An optimal imaging system includes simultaneous visible (white) light illumination of the surgical field, which can be merged with the generated NIR fluorescence images. The surgeon's display can be one of several form factors, including a standard computer monitor, goggles or a wall projector. Current imaging systems operate at a sufficient working distance that enables the surgeon to operate and illuminates a sizable surgical field. Abbreviations: LED, light-emitting diode; NIR, near-infrared.
fluores cence imaging during surgery. Indeed, studies have shown that NIR fluorescence imaging outperforms blue dyes because of increased tissue penetration and the lack of staining of the patient and surgical field. 64, 66, 89 However, as current imaging systems in combination with ICG demonstrate depth penetration <5-10 mm, ongoing studies (A. L. Vahrmeijer et al., unpublished work) are assessing the noninferiority of NIR fluorescence compared with radioactivity, which is of particular clinical importance in cases where lymph nodes are located deeply within the patient, for example in obese patients.
Combining NIR fluorescence with radioimaging
To overcome the issue of limited depth penetration, a combination of NIR fluorescence and imaging using radioactive tracers has been reported for SLN mapping. 17, 35, 63, 82 This combination is complementary: the superior depth penetration of radioactivity is used to perform gross navigation to the SLN, after which the superior spatial and temporal resolution of NIR fluorescence facilitates image-guided identification and resection of the SLN. When a preoperatively injected, combined NIR fluorescent and radioactive tracer is used (for example, ICG adsorbed to albumin nanocolloid), no intraoperative injection of tracer is necessary. A preoperative injection by the nuclear medicine physician suffices for both preoperative lymphoscintigraphy and intraoperative SLN detection, reducing the duration of surgery, anaesthesia and, potentially, costs. 17, 35, 63, 82 Targeted SLN tracers An optimal tracer for SLN mapping migrates quickly from the injection site to the lymph node and remains in the first draining node without migrating to higher tier nodes. To prevent migration to higher tier nodes, radiotracers are commonly conjugated to a colloid to increase the hydrodynamic diameter or to a ligand to increase retention. In the USA, a sulphur-based colloid is most widely used, whereas in Europe, an albumin-based colloid is commonly used. 61 However, the choice of conjugant can affect the optical properties of the tracer. For example, ICG cannot be conjugated covalently to sulphur colloids without altering its chemical structure, which is critical to its optical performance, although non covalent adsorption of ICG albumin nanocolloid seems to work well, because of the affinity of ICG for albumin itself. 15, 90 A novel strategy for lymph-node retention has been developed by Vera and colleagues, who created a lymphatic tracer specific for a receptor (mannose-binding protein) found on reticuloendothelial cells of lymph nodes, which effectively prevents migration to higher tier nodes. 91 Although this tracer was primarily designed for radiolabelling, studies have been published in which this tracer is conjugated to a fluorescent label. 16, 92 In phase II clinical studies, the radiolabelled tracer has demonstrated adequate identification of SLNs, leading to FDA approval for SLN identification. 93, 94 However, the performance of this tracer, in direct comparison to e xisting agents, has yet to be evaluated. 
Tumour imaging
The use of ICG in SLN mapping has paved the way for NIR fluorescence imaging in the operating room; however, one of the key applications in cancer surgery is intraoperative tumour visualization. To visualize tumours using NIR fluorescence imaging, the contrast agent should accumulate in or around the tumour. Methods for tumour-targeting include the use of antibodies or peptides specific for cell-surface receptors, agents that are activated by tumour-specific enzymatic activity and agents that target increased metabolic activity. 95, 96 Although a variety of tumour-specific NIR fluores cent contrast agents have been developed and applied preclinically, none of these has yet obtained full clinical approval by either the FDA or the EMA. Using the clinically available, yet nonspecific, contrast agents ICG, methylene blue and 5-ALA, first-in-human intraoperative tumour imaging studies have been described in various cancer types.
Indocyanine green
After intravenous administration, ICG is cleared by the liver, 53 potentially enabling intraoperative identification of hepatic lesions. In 2006, Horowitz and colleagues proposed a mechanism by which ICG accumulated in tumours in their study of ovarian cancer metastases. 97 That is, after intravenous injection, ICG binds to plasma proteins, which increases its hydrodynamic diameter. This change enables ICG to accumulate in tumours because of enhanced permeability and retention.
Ishizawa and colleagues were the first to demonstrate clear visualization of both colorectal hepatic metastases and hepatocellular carcinomas (HCC) using ICG NIR fluorescence imaging. 98 In their study and subsequent studies, several hours to days after intravenous injection of ICG, a fluorescent rim could be visualized intraoperatively around hepatic metastases, or in the case of HCCs, fluorescence was observed in the tumour itself. Notably, the surrounding healthy liver parenchyma displayed almost no background signal. [99] [100] [101] Tumours that could be visualized using NIR fluorescence imaging were all relatively superficial (<8 mm below the surface of the liver), and tumours located deeper than 8 mm could not be visualized. Several other clinical studies have reported on NIR fluorescence imaging results using ICG in patients with HCC. 29, 98 Surprisingly, in contrast to hepatic metastases, ICG accumulated in the HCC tumours, as opposed to the accumulation in a rim around colo rectal liver metastases. Although this suggests a different mecha nism of accumulation, any accumulation method could be effective for clinical identification purposes.
Intraoperative ultrasonography is routinely used before resection of hepatic tumours to identify any masses that were not detected on preoperative imaging, in conjunction with intraoperative inspection and palpation. One of the main limitations of intraoperative ultrasonography is the hampered detection of superficial and small tumours. 102 By contrast, NIR fluorescence imaging performs well in this setting, but is unable to visualize deeper tumours (>5-8 mm below the surface). Thus, in liver surgery, NIR fluorescence imaging can be a potential adjunct to conventional imaging techniques for the preoperative and intraoperative detection of primary hepatic tumours and metastases.
Satou and colleagues used NIR fluorescence imaging after ICG injection to identify extrahepatic metastases of HCC. 103 They reported the detection of five metastases that were not detected by preoperative CT imaging in two out of 17 patients (11.7%), confirming the complementary value of NIR fluorescence imaging. Yokoyama and colleagues identified hepatic metastases of pancreatic carcinoma that were otherwise not detected by preoperative CT or MRI-or intraoperatively by ultra sonography, visual inspection or palpation-in eight out of 49 patients (16.3%), potentially preventing those patients from unnecessary radical resections and associ ated morbidity. 104 Our own group found that, in five of 40 patients (12.5%), ICG-based NIR fluorescence imaging detected colorectal metastases in the liver that were otherwise undetectable by preoperative CT, intraoperative ultrasonography, palpation and visualization. 48 As might be expected, all detectable metastases were <8 mm from the liver surface.
Finally, a novel and rapidly expanding field of NIRfluorescence-guided cancer surgery is related to neurosurgery. ICG has been used to intraoperatively identify high-grade gliomas, meningiomas, haemangioblastomas and pituitary tumours. [105] [106] [107] These tumours can be visual ized via the intravenous administration of 5-25 mg ICG. Although the first studies show promising results, a direct comparison with the more-extensively studied 5-ALA-induced PpIX fluorescence has yet to be reported.
Methylene blue
Methylene blue has previously been described to stain the parathyroid glands and insulinomas after high-dose (100 mg/kg) intravenous and intra-arterial injection, respectively. 108, 109 However, the mechanism of methylene blue accumulation has not yet been identified. Winer and colleagues demonstrated in their preclinical study that dilute methylene blue (0.25-2 mg/kg) can be used as an NIR fluorescent contrast agent for identifying insulino mas. 50 Although clinical use of methylene blue for insulinomas has not yet been reported, it was successfully used to visualize a rare s olitary fibrous tumour of the pancreas in a patient. 52 Protoporphyrin IX 5-ALA-induced PpIX has been studied extensively in the field of neurosurgery, mostly for the intraoperative identi fication of brain tumours, such as malignant gliomas. 57, 110 Stummer et al. 57 compared conventional white-light visualization with (visible) fluorescence imaging for intraoperative visualization of malignant glioma in a random ized controlled trial. They showed that visualization of PpIX fluorescence after oral 5-ALA administration led to a significant increase in the rate of complete resection (65% versus 36%, P <0.0001), improved the 6-month progression-free survival (41% versus 21%, P = 0.0003), fewer reinterventions and delayed onset of neurological deterioration. Furthermore, 5-ALA-induced PpIX has been used to identify urothelial bladder cancer during (visible) fluorescence-guided cystoscopy in c omparison with conventional white-light imaging. 111 Topical contrast agents Aside from systemically injected contrast agents, topical application of NIR fluorescence contrast agents can be used to identify tumours intraoperatively. Indeed, such topical agents have been used in colonoscopic (sprayed on suspected regions endoscopically) 112 or cystoscopic procedures (instilled in the bladder during cystoscopy); 113 5-ALA and its derivatives have been described in bladder cancer. [113] [114] [115] Kriegmair and colleagues reported both conventional white-light imaging and fluorescence imaging after 5-ALA instillation during cystoscopy in 104 patients, in which they identified 35 additional lesions that could not be visualized by conventional white-light imaging. 113 Although visible (red) light fluorescence was used for imaging in these studies, PpIX synthesized by the tumour cells has half its emission spectrum in the NIR range, and can be detected accordingly.
Imaging of vital structures
Iatrogenic damage to vital structures occurs frequently during cancer surgery. For example, nerve damage is common and can lead to postoperative pain or loss of specific functions, such as incontinence or impotence, especially in rectal cancer or prostate cancer surgery. 116, 117 Damage to the ureters or bile duct is rare, but associated with severe complications, such as renal dysfunction and biliary peritonitis. 118, 119 Damage to these structures is usually a result of inadequate identification during surgery; for example, ureters can be difficult to visualize because they are located in the pelvis, and if the tumour or inflamed tissue is covering them. NIR fluorescence imaging has been described as a p ossible solution to these important surgical issues.
As ICG is cleared by the liver and excreted into the bile ducts, studies have described intraoperative NIR fluorescence cholangiographies after its intravenous administration. 39, 120 Using methylene blue, which is predominantly cleared by the kidneys, the ureters could be intraoperatively identified using NIR fluorescence imaging (Figure 2) . 51 The increased depth penetration of NIR fluorescence can, therefore, be of added value over visible light imaging. NIR fluorescence imaging can also be of particular benefit in laparoscopic and robotassisted surgery, in which there is diminished tactile feedback. NIR fluorescence-capable fiberscopic systems are now readily available for these applications. 35, 38, 74 Finally, subcutaneously administered ICG has been used in multiple clinical studies to visualize lymphatic flow in real time, which will likely aid in understanding the mechanism of lymphedoema, a morbid complication of several cancer surgeries. 68, 121 Vascular perfusion Anastomoses Anastomotic leaks after intestinal surgery for cancer are a common and severe complication, with incidence rates between 0.5% and 7%. 122, 123 These leaks are presumably caused by insufficient perfusion of an intestinal anastomosis. 124 Given that NIR fluorescence imaging can be used to visualize blood perfusion after intravenous injection of ICG, several groups have reported on its ability to assess anastomotic blood perfusion after intestinal surgery. [124] [125] [126] Although retrospectively studied, Kudszus and colleagues described a 60% reduction in the risk of revision because of anastomotic leak in patients whose anastomoses were examined using NIR fluorescence angiography (n = 332) compared with h istorically matched patients without imaging (n = 306). 124 
Flaps in reconstructive surgery
Vessel identification and selection is essential during cancer reconstructive surgery using free or pedicled flaps. NIR fluorescence imaging provides the opportunity to identify vessels intraoperatively and to assess perfusion in these flaps. 127, 128 In breast reconstruction surgery, for example, NIR fluorescence angiography has been used for vessel identification and selection, and to monitor venous outflow. 129, 130 Newman and colleagues described that arterial and venous problems were identified intraoperatively in four out of eight patients undergoing breast reconstructive surgery, which changed the operative plan in three out of four cases (for example, by debriding avital tissue, or including additional perforating vessels), leading to a 100% flap survival outcome. 129 Although larger patient studies should be performed, these results suggest that NIR fluorescence imaging could improve flap survival and patient outcome in reconstructive surgery using free or pedicled flaps.
Current developments
Clinical studies have demonstrated the feasibility of intraoperative imaging using NIR fluorescence in various applications. However, these studies are based on contrast agents that were already available clinically, but not specifically developed for this purpose. To determine the true clinical benefit of this technique, developing and clinically assessing contrast agents tailored to specific applications is essential.
Imaging systems
As we progress towards using multiple targeted NIR fluorophores (the so-called cocktail of contrast agents), the possibility of visualizing multiple contrast agents simultaneously would be beneficial. For this purpose, imaging systems are in development that can simultaneously detect fluorescence from multiple wavelengths. 30, 32 Furthermore, techniques are being implemented to discriminate between contrast agents that emit at a similar wavelength. 131, 132 Finally, ergonomics, both physical and in terms of the software and advanced algorithms (for image processing and user interaction) used to improve the efficiency of clinical workflow, should be a focus of attention during imaging system design.
Contrast agents
The development of novel NIR fluorescent contrast agents is dependent on the availability of clinically compatible fluorophores. Although many fluorophores have been evaluated in the preclinical setting, to date only two novel fluorophores have been reported to be in the process of clinical translation: IRDye 800CW (LI-COR Biosciences, Lincoln, NE) and ZW800-1 (The FLARE Foundation, Wayland, MA). 23, 133 Both compounds are small molecules, characterized as nontoxic in initial toxicity studies and can be conjugated to targeting moieties, such as tumour-specific small molecules, peptides or antibodies. 13, 134 In addition, the clearance mechanisms of these agents-renal clearance for ZW800-1 and the combined renal and hepatic clearance for IRDye 800CW-enable these agents to be used for imaging of ureters and bile ducts. 23, 135 Clinically approved (for therapeutic applications) targeted antibodies are available for various tumours and tumour markers, including, for example, bevacizumab against VEGF, cetuximab against EGFR and trastuzumab against HER2. 136 Combining these already approved antibodies with an NIR fluoro phore could usher in a new generation of NIR-fluorescent contrast agents. Indeed, the first clinical trial on intraoperative tumour visualization in patients with breast cancer using bevacizumab conjugated to IRDye 800CW has been approved and is currently accruing patients.
137
In addition to antibodies, other targeting moleculessuch as peptides-have been successfully translated into the clinic using radiolabeling and suggest potential for NIR fluorescence imaging. For example targeting integrin α V β 3 , which is upregulated in a variety of cancer types, including breast cancer and colorectal cancer, using cyclic arginine-glycine-aspartic acid (cRGD) has been demonstrated clinically in PET studies. 138 A fluoro phore conjugated to this peptide (cRGD-ZW800-1) has been used for tumour-specific imaging after intra venous injection in a preclinical study. 13 Although useful for target ing specific antigens, whole antibodies conjugated to fluorophores are typically very large, which limits their ability to leave the blood stream, increases blood half-life and potentially increases background signal. To overcome this disadvantage, investigational contrast agents such as nanobodies are being developed using smaller antigenbinding fragments. 139 Nanobodies have smaller hydrodynamic diameters than antibodies and can, therefore, extravasate more easily, even in areas of high interstitial pressure (that is, solid tumours). 134, 139 Indeed, nanobodies against EGFR have been shown to outperform whole antibodies for tumour imaging in terms of probe uptake in tumour cells and hetero geneous distribution within tumours. 134 As hetero geneity in tumours is an important problem when selecting a targeting ligand, 140 a 'cocktail' of several targeted NIR fluorophores will likely be needed for e ffective clinical practice.
To visualize nerves, several research groups are develop ing specific contrast agents. One approach is focused on a family of fluorescent dyes that bind to the myelin of neurons. 141 However, these contrast agents currently fluoresce in the nonoptimal visible spectrum. Another approach is the use of NIR fluorescent peptides that bind to nerve sheaths. 25 To date, no clinical trial has been reported on nerve-specific agents, although the field eagerly awaits such a development.
A distinct class of NIR fluorescent contrast agents encompasses 'activatable' agents. These agents are nonfluorescent or low-fluorescent in the unactivated state, often due to autoquenching of the fluorophores, but become fluorescent after activation by a molecular target, such as a tumour-specific enzyme. For example, Weissleder and colleagues developed an agent that was low-fluorescent because of autoquenching of fluorophores on a polymer backbone, but that became fluores cent upon cleavage of the backbone by cleaving of the backbone by proteases. 12 Preclinical studies show adequate tumour detection after intravenous injection of activatable agents. 12, 14, 49, 142, 143 Other reports show rapid tumour visualization after topical application of activatable agents. 144 If indeed these agents are only activated at their target site (tumour cells), potential benefits include lower background fluorescence signal and, therefore, higher tumour-to-background ratios. Several of these agents are in the process of obtaining regulatory approval for proof-of-principle trials; however, to date no such trials are approved and a ccruing patients.
Key clinical parameters
Optimal visualization is achieved by maximizing the signal-to-background ratio to maximize contrast. The chosen target, type of contrast agent, route of administration (intravenous, local injection or topical spray) and the imaging goal (SLN mapping, tumour imaging or other structures) all must be factored in to achieve optimal visualization. Perhaps the most important parameter for imaging is the target. Is it an abundant receptor on the cell surface, a subcellular organelle, or the substrate for a membrane transporter? Given that all fluorescent techniques rely on concentration, the abundance and availability of the target are key concerns. For example, a cell surface receptor with a total number of receptors per cell (B Max ) of 10 4 can only achieve a fluorophore concentration of approximately 17 nM, assuming a 1:1 ratio of targeted NIR fluorophore to receptor. Even the most highly abundant receptors, with a B Max of 10 5 -10 6 can only achieve a concentration of a pproximately 1 μM. 2 The utility of NIR imaging is dependent on the pharmacokinetic properties of the contrast agents. For example, within the first few seconds after intravenous injection, NIR fluorescent contrast agents highlight the arterial system and then the venous system (Figure 3) . Over the next minutes to hours, hepatic and renal clearance will occur in parallel with tissue bio distribution and target binding. Some NIR fluorophores, such as methylene blue, accumulate in endocrine cells by unknown mechanisms. 50 Others, including antibodybased agents such as bevacizumab-800CW, 137 are either targeted to particular receptors or membrane transporters, or accumu late passively because of structural abnormalities in the tissue (for example, the enhanced permeability and retention [EPR] effect). 145 As the EPR effect contributes to accumulation in tumour tissue in targeted-contrast agents as well, nonspecific control agents are necessary to determine the amount of a ccumulation caused by the EPR effect.
As the contrast agent clears from the bloodstream and normal tissues, but is hopefully retained in the tumour tissue, the signal-to-background ratio at the target site increases. To determine the necessary dose and timing, extensive dosing, biodistribution and pharmacokinetic studies are essential. For example, an imaging time that is too short relative to clearance will result in a low signal-to-background ratio because of high background fluores cence. Conversely, an imaging time that is too long relative to the time it takes for the contrast agent to bind the target will result in a low signal-to-background ratio because of signal loss. 8, 96 Limitations and leverage Despite improved tissue penetration when compared to visible light, an essential limitation of NIR fluorescence imaging remains the inability to visualize structures more than approximately 5-8 mm below the surface using current reflectance-based systems. Rather than introduce increasingly complex optical methods, such as tomography, into surgery, the field has been migrating towards combining reflectance optical imaging with other modalities. Imaging modalities based on radioactive tracers, such as preoperative PET and singlephoton emission computed tomography, intraoperative gamma probes and gamma cameras have depth sensitivities up to several centimetres, but cannot provide precise real-time visualization. 82, 146 Combining NIR fluorescence imaging with these modalities, as well as intraoperative ultrasonography, leverages the key benefits of each technique individually, and overcomes the limited penetration depth of NIR light (Figure 4) . 147 Another major limitation is the lack of clinically available targeting agents, which can be attributed to the high cost 148 and complex regulatory requirements surrounding drug development. Nevertheless, several academic and commercial groups have made progress on the clinical translation and several first-in-human clinical trials of new NIR fluorophores will commence within the next 2-3 years.
Path to routine patient care
NIR fluorescence imaging has proven feasible during surgery in many clinical studies. However, the main question is when will the technique become part of routine patient care. In the past, the adoption of a new technology had to satisfy only two major cri teria. Firstly, the methodology needed to change patient management; that is, make a meaningful impact on care. Secondly, it had to be clinically 'realistic' in that normal workflows would not be compromised or changed. 8 However, as insurance companies and govern ments try to reign in health-care spending, techno logy must also make patient care faster, better and cheaper. Optical imaging is one of the few techno logies with the potential to satisfy all three criteria. NIR fluorescence enables intraoperative imaging in real time, without impeding the current clinical workflow. If surgeons are able to find tumours or avoid normal structures more easily than without these tools, operating room time could be shortened, which reduces anaesthesia time and its associated risks. Furthermore, such a reduction in surgical time per patient would enable more patients to be treated each day and facilitate hospitals in improving resource distribution. Finally, improved tumour resections that avoid normal tissues entirely will subsequently lower rates of recurrence and complication, which will further drive down costs to the health-care system. However, quantification of these potential benefits will require well-designed, well-execute d clinical trials.
Conclusions
NIR fluorescence image-guidance during cancer surgery has the potential to improve patient management by visualizing tissue demarcation in real time, thereby increasing the completeness of surgery and decreasing the morbidity associated with damage to normal structures. Intraoperative imaging requires a synchronous interplay between contrast agents, tumour biology, imaging systems and image-analysis algorithms.
Results to date using available contrast agents and firstgeneration imaging systems are extremely promising. However, because of the relatively low depth of penetration, NIR fluorescence imaging will likely be a complementary adjuvant to other imaging modalities (such as ultrasonography and radioscintigraphy) in some clinical applications. Although studies focused on patient outcomes and health-care resource utilization should begin using existing imaging systems and nontargeted contrast agents, the era of targeted contrast agents for specific cancers remains tantalizingly close. Given the interest in the field, the next decade should clarify the role of NIR fluorescence imaging in cancer surgery and the extent to which it empowers surgeons to improve patient outcomes. , can be located using NIR fluorescence imaging. However, a deeper target (at 25 mm) would be invisible using by NIR fluorescence imaging alone. b | Combining NIR fluorescence imaging with radioscintigraphy enables visualization of all three targets. However, the spatial and temporal resolution of radioscintigraphy is poor. Once overlying tissue is surgically removed as guided by radioscintigraphy, NIR fluorescence can be used for more-precise image guidance. c | Intraoperative ultrasonography can visualize targets that are located deeper in tissue than NIR imaging, but fails to find superficially located targets because of high acoustic reflectance. However, these superficial targets can be visualized by NIR fluorescence. Of note, the ultrasound probe must be in direct contact with the tissue being imaged, precluding simultaneous imaging with NIR fluorescence. Abbreviation: NIR, near-infrared.
Review criteria
We searched for original articles focusing on intraoperative near-infrared fluorescence imaging in MEDLINE and PubMed published between 1980 and 2013. The search terms we used were "near-infrared fluorescence", "intraoperative imaging", "indocyanine green", "methylene blue", and "aminolevulinic acid". All papers identified were English-language full-text papers. We also searched the reference lists of identified articles for further papers.
